ArticleACS omega2026
Oleic Acid-Modified Oligochitosan Nanoparticles Preserve Bacteriophage Lytic Activity against Clinical
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) lung infections are recurrent and frequently associated with multidrug-resistant bacteria, limiting the efficacy of the currently available antibiotic therapies. Bacteriophages have emerged as a promising alternative; however, their clinical translation is constrained by their limited stability and inefficient delivery within the airway microenvironment. Here, oleic acid-modified oligochitosan (OCS-OA) nanoparticles were developed as controlled-release nanocarriers to promote bacterial clearance during infection. Three OCS-OA formulations (10, 20, and 30% OA substitution) were modified via an amidation reaction and confirmed by attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR). Surface tension analysis demonstrated the amphiphilic behavior and self-assembly of the modified oligosaccharides into micelle-like nanostructures. The bacteriophage (vB_Eco_K-02) was efficiently encapsulated (>90%), and the resulting formulations were characterized by scanning transmission electron microscopy (STEM), atomic force microscopy (AFM), dynamic light scattering (DLS), and ζ-potential. Formulations prepared with 10 and 20% OCS-OA preserved phage lytic activity against a clinical
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.